Opendata, web and dolomites


Exome Sequencing in stages of Treatment REsistance to Antidepressants

Total Cost €


EC-Contrib. €






Project "ESTREA" data sheet

The following table provides information about the project.


Organization address
address: STRAND
city: LONDON
postcode: WC2R 2LS

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 137˙591 €
 EC max contribution 137˙591 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KING'S COLLEGE LONDON UK (LONDON) coordinator 137˙591.00


 Project objective

This project will address the emerging healthcare problem of Treatment Resistant Depression (TRD). Major Depressive Disorder (MDD) is a major social and clinical burden, responsible for ~15% of all days lived with disability in EU. Treatment challenges arise from the different biological dysfunctions implicated in different patients and the lack of biomarkers available to guide the choice of anti-depressants. Preliminary evidence suggests that genetic variants may be useful in making treatment choices, but further work to identify relevant variants is needed. Previous pharmacogenetic studies have focused on identifying common genetic variants associated with antidepressant response. The role of rare variants has not been well studied and few studies have investigated the genetics of TRD (patients with two or more failed treatments). This project will combine exome sequencing and genome-wide genotyping in the unique GSRD sample of 1346 MDD patients characterized for stages of treatment resistance (number of failed treatments). This study aims to identify both rare and common variants associated with stages of resistance, the first such study to be performed. The analysis will focus on genes and pathways instead of single variants, since the cumulative effect of a number of variants is likely to disrupt the functionality of a gene or pathway. The study will assess the impact of clinical variables on genetic finding, and develop a genomic profile for TRD which can be used to guide treatment in patients. These findings will be used to design a prospective clinical trial to test the cost-effectiveness of the TRD genetic markers. I will seek funding sources to implement the trial, an essential step to translate the findings to the clinic. This personalised medicine study should facilitate the development of new evidence-based treatments and substantially reduce the time to identify the best treatment strategy in MDD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESTREA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ESTREA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

The Damned (2020)

Algeria, antifascism, and Third Worldism: An anticolonial genealogy of the Western European New Left (Algeria, France, Italy, 1957-1975)

Read More  

InProSMod (2021)

Cholinergic and NMDAR-dependent recruitment of Layer 1 Interneuron shapes cortical motor Processing through network States Modulation

Read More  

GWFP (2019)

Geometric study of Wasserstein spaces and free probability

Read More